Header Logo

XUELIN HUANG

TitleProfessor
InstitutionMD Anderson
DepartmentBiostatistics
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol. 2015 Sep; 90(9):769-73. PMID: 26017166; PMCID: PMC4546505.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    2. Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15; 121(4):556-61. PMID: 25336333; PMCID: PMC4320000.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    3. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):152-8. PMID: 25445468; PMCID: PMC4344896.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    4. Burger JA, Keating MJ, Wierda WG, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Zacharian G, Huang X, Kantarjian H, Garg N, O'Brien S, Hartmann E, Nogueras-Gonz?lez GM, Rosenwald A. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep; 15(10):1090-9. PMID: 25150798; PMCID: PMC4174348.
      Citations: 131     Fields:    Translation:HumansCTClinical Trials
    5. Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, Han L, Huang X, Lawrence MS, Weinstein JN, Stuart JM, Mills GB, Garraway LA, Margolin AA, Getz G, Liang H. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol. 2014 Jul; 32(7):644-52. PMID: 24952901; PMCID: PMC4102885.
      Citations: 124     Fields:    Translation:Humans
    6. Mak PY, Mak DH, Mu H, Shi Y, Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Wei W, Huang X, Kornblau SM, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML. Apoptosis. 2014 Apr; 19(4):698-707. PMID: 24337870; PMCID: PMC3943601.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    7. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2226-35. PMID: 24583795; PMCID: PMC3989412.
      Citations: 37     Fields:    Translation:HumansCellsCTClinical Trials
    8. Huang X, Ning J, Wahed AS. Optimization of individualized dynamic treatment regimes for recurrent diseases. Stat Med. 2014 Jun 30; 33(14):2363-78. PMID: 24510534; PMCID: PMC4043865.
      Citations: 6     Fields:    Translation:Humans
    9. Choi S, Kantarjian H, Jabbour E, Huang X, Cortes J, Quint?s-Cardama A. Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):327-334.e8. PMID: 24594142; PMCID: PMC4099320.
      Citations: 6     Fields:    Translation:Humans
    10. Jabbour E, Ghanem H, Huang X, Ravandi F, Garcia-Manero G, O'Brien S, Faderl S, Pierce S, Choi S, Verstovsek S, Brandt M, Cortes J, Kantarjian H. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):93-7. PMID: 24447728; PMCID: PMC4098769.
      Citations: 6     Fields:    Translation:HumansCells
    11. Pierceall WE, Kornblau SM, Carlson NE, Huang X, Blake N, Lena R, Elashoff M, Konopleva M, Cardone MH, Andreeff M. BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia. Mol Cancer Ther. 2013 Dec; 12(12):2940-9. PMID: 24092807; PMCID: PMC3881173.
      Citations: 19     Fields:    Translation:Humans
    12. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6. PMID: 23877926; PMCID: PMC4110914.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    13. Rao X, Lai D, Huang X. A new method for quantitative real-time polymerase chain reaction data analysis. J Comput Biol. 2013 Sep; 20(9):703-11. PMID: 23841653; PMCID: PMC3762066.
      Citations: 20     Fields:    
    14. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21. PMID: 23836561; PMCID: PMC3976223.
      Citations: 77     Fields:    Translation:HumansCells
    15. Matin SF, Cormier JN, Ward JF, Pisters LL, Wood CG, Dinney CP, Royal RE, Huang X, Pettaway CA. Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU Int. 2013 Jun; 111(7):1068-74. PMID: 23551693; PMCID: PMC3651805.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    16. Choi S, Huang X. A general class of semiparametric transformation frailty models for nonproportional hazards survival data. Biometrics. 2012 Dec; 68(4):1126-35. PMID: 23005582; PMCID: PMC3530665.
      Citations:    Fields:    
    17. Luo S, Yi M, Huang X, Hunt KK. A Bayesian model for misclassified binary outcomes and correlated survival data with applications to breast cancer. Stat Med. 2013 Jun 15; 32(13):2320-34. PMID: 22996169; PMCID: PMC3897718.
      Citations: 2     Fields:    Translation:Humans
    18. Cai G, Li H, Lu Y, Huang X, Lee J, Ji Y, Liang S, M?ller P. Accuracy of RNA-Seq and its dependence on sequencing depth. BMC Bioinformatics. 2012; 13 Suppl 13:S5. PMID: 23320920; PMCID: PMC3426807.
      Citations: 11     Fields:    
    19. Huang X, Ning J. Analysis of multi-stage treatments for recurrent diseases. Stat Med. 2012 Oct 30; 31(24):2805-21. PMID: 22826139; PMCID: PMC3500149.
      Citations: 5     Fields:    Translation:Humans
    20. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012 Jul 05; 120(1):173-80. PMID: 22645176; PMCID: PMC3390955.
      Citations: 49     Fields:    Translation:HumansCells
    21. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51. PMID: 22534616; PMCID: PMC3859239.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    22. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20. PMID: 22360602; PMCID: PMC3924750.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    23. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012 Jun 15; 118(12):3123-7. PMID: 22294282; PMCID: PMC3342429.
      Citations: 95     Fields:    Translation:Humans
    24. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15; 118(18):4471-7. PMID: 22282348; PMCID: PMC3907176.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    25. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012 Mar 01; 119(9):1981-7. PMID: 22228624; PMCID: PMC3311242.
      Citations: 108     Fields:    Translation:Humans
    26. Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, Shpall E, Huang X, Andreeff M. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1a-mediated down-regulation of CXCL12. Blood. 2011 Oct 20; 118(16):4431-9. PMID: 21868571; PMCID: PMC3204912.
      Citations: 53     Fields:    Translation:HumansCells
    27. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011 Jun 20; 29(18):2507-13. PMID: 21555694; PMCID: PMC4874214.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    28. Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med. 2011 May 20; 30(11):1218-29. PMID: 21432894; PMCID: PMC3086983.
      Citations: 7     Fields:    Translation:Humans
    29. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1a) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011 Feb 03; 117(5):1662-9. PMID: 21115978; PMCID: PMC3318778.
      Citations: 61     Fields:    Translation:Humans
    30. Ning J, Huang X. Response-adaptive randomization for clinical trials with adjustment for covariate imbalance. Stat Med. 2010 Jul 30; 29(17):1761-8. PMID: 20658546; PMCID: PMC2911996.
      Citations: 7     Fields:    Translation:Humans
    31. Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS, Appelbaum FR, Estey EH. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol. 2010 Apr 01; 28(10):1766-71. PMID: 20159819; PMCID: PMC2849766.
      Citations: 71     Fields:    Translation:Humans
    32. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma. 2010 Jan; 51(1):73-8. PMID: 20017599; PMCID: PMC2876330.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    33. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010 Feb 01; 28(4):605-13. PMID: 20038729; PMCID: PMC2815995.
      Citations: 121     Fields:    Translation:HumansCells
    34. Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, Garcia-Manero G, Chen W, Medeiros LJ, Bueso-Ramos CE. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer. 2009 Oct 15; 115(20):4737-44. PMID: 19637342; PMCID: PMC4199225.
      Citations: 12     Fields:    Translation:HumansCells
    35. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10; 27(32):5425-30. PMID: 19805674; PMCID: PMC4881363.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    36. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia. 2009 Dec; 23(12):2275-80. PMID: 19741728; PMCID: PMC4217206.
      Citations: 27     Fields:    Translation:Humans
    37. Huang X, Ning J, Li Y, Estey E, Issa JP, Berry DA. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Stat Med. 2009 May 30; 28(12):1680-9. PMID: 19326367; PMCID: PMC2883264.
      Citations: 13     Fields:    Translation:Humans
    38. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2009 Jul; 23(7):1297-302. PMID: 19242494; PMCID: PMC4217203.
      Citations: 19     Fields:    Translation:HumansAnimalsCTClinical Trials
    39. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008 Oct 15; 113(8):2090-6. PMID: 18756533; PMCID: PMC4163782.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    40. Liu L, Huang X. The use of Gaussian quadrature for estimation in frailty proportional hazards models. Stat Med. 2008 Jun 30; 27(14):2665-83. PMID: 17910008; PMCID: PMC7364854.
      Citations: 27     Fields:    Translation:Humans
    41. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 01; 112(5):1638-45. PMID: 18565853; PMCID: PMC4081352.
      Citations: 67     Fields:    Translation:Humans
    42. Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer. 2008 May 01; 112(9):2030-7. PMID: 18320602; PMCID: PMC4207058.
      Citations: 3     Fields:    Translation:Humans
    43. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008 Feb 15; 112(4):837-45. PMID: 18085610.
      Citations: 41     Fields:    Translation:HumansCells
    44. Huang X, Zhang N. Regression survival analysis with an assumed copula for dependent censoring: a sensitivity analysis approach. Biometrics. 2008 Dec; 64(4):1090-9. PMID: 18266895; PMCID: PMC4037927.
      Citations: 9     Fields:    Translation:Humans
    45. Cook RJ, Zeng L, Lee KA. A multistate model for bivariate interval-censored failure time data. Biometrics. 2008 Dec; 64(4):1100-9. PMID: 18218064.
      Citations: 3     Fields:    Translation:Humans
    46. Liu L, Huang X, O'Quigley J. Analysis of longitudinal data in the presence of informative observational times and a dependent terminal event, with application to medical cost data. Biometrics. 2008 Sep; 64(3):950-958. PMID: 18162110.
      Citations: 28     Fields:    Translation:Humans
    47. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008 Mar; 22(3):538-43. PMID: 18079733.
      Citations: 101     Fields:    Translation:Humans
    48. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15; 111(4):1816-9. PMID: 18039954.
      Citations: 23     Fields:    Translation:HumansCells
    49. Yanada M, Huang X, Garcia-Manero G, O'brien S, Ravandi F, Borthakur G, Faderl S, Issa JP, Kantarjian H, Estey E. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. Br J Haematol. 2007 Aug; 138(4):555-7. PMID: 17593249.
      Citations: 1     Fields:    Translation:Humans
    50. Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A parallel phase I/II clinical trial design for combination therapies. Biometrics. 2007 Jun; 63(2):429-36. PMID: 17688495.
      Citations: 35     Fields:    Translation:Humans
    51. Huang X, Liu L. A joint frailty model for survival and gap times between recurrent events. Biometrics. 2007 Jun; 63(2):389-97. PMID: 17688491.
      Citations: 36     Fields:    Translation:Humans
    52. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007 Mar 15; 109(6):1133-7. PMID: 17315156; PMCID: PMC2952542.
      Citations: 60     Fields:    Translation:Humans
    53. Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 2007 Mar 15; 109(6):1152-6. PMID: 17315232.
      Citations: 66     Fields:    Translation:Humans
    54. Huang X, Cormier JN, Pisters PW. Estimation of the causal effects on survival of two-stage nonrandomized treatment sequences for recurrent diseases. Biometrics. 2006 Sep; 62(3):901-9. PMID: 16984334.
      Citations: 4     Fields:    Translation:Humans
    55. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7. PMID: 16882708.
      Citations: 243     Fields:    Translation:HumansCells
    56. Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006 May 01; 106(9):2012-20. PMID: 16568458.
      Citations: 27     Fields:    Translation:Humans
    57. Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006 Jun 15; 107(12):4658-62. PMID: 16497968.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    58. Huang X, Biswas S, Estey EH, Berry DA. Building and validating a prognostic index for biomarker studies. Cancer Biomark. 2006; 2(3-4):97-101. PMID: 17192064.
      Citations: 1     Fields:    Translation:Humans
    59. Shen Y, Huang X. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening trial. Biometrics. 2005 Dec; 61(4):992-9. PMID: 16401272.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    60. Phongkitkarun S, Kobayashi S, Varavithya V, Huang X, Curley SA, Charnsangavej C. Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT. Clin Radiol. 2005 Jun; 60(6):700-9. PMID: 16038698.
      Citations: 6     Fields:    Translation:Humans
    61. Cormier JN, Huang X, Xing Y, Thall PF, Wang X, Benjamin RS, Pollock RE, Antonescu CR, Maki RG, Brennan MF, Pisters PW. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol. 2004 Nov 15; 22(22):4567-74. PMID: 15542808.
      Citations: 34     Fields:    Translation:Humans
    62. Liu L, Wolfe RA, Huang X. Shared frailty models for recurrent events and a terminal event. Biometrics. 2004 Sep; 60(3):747-56. PMID: 15339298.
      Citations: 90     Fields:    Translation:Humans
    63. Huang X, Wolfe RA, Hu C. A test for informative censoring in clustered survival data. Stat Med. 2004 Jul 15; 23(13):2089-107. PMID: 15211605.
      Citations:    Fields:    Translation:Humans
    64. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol. 2004 Jul; 17(7):790-7. PMID: 15073602.
      Citations: 35     Fields:    Translation:Humans
    65. Chang KC, Huang X, Medeiros LJ, Jones D. Germinal centre-like versus undifferentiated stromal immunophenotypes in follicular lymphoma. J Pathol. 2003 Nov; 201(3):404-12. PMID: 14595752.
      Citations: 11     Fields:    Translation:HumansCells
    66. Van Harrison R, Janz NK, Wolfe RA, Tedeschi PJ, Stross JK, Huang X, McMahon LF. Characteristics of primary care physicians and their practices associated with mammography rates for older women. Cancer. 2003 Nov 01; 98(9):1811-21. PMID: 14584062.
      Citations: 11     Fields:    Translation:Humans
    67. Harrison RV, Janz NK, Wolfe RA, Tedeschi PJ, Huang X, McMahon LF. 5-Year mammography rates and associated factors for older women. Cancer. 2003 Mar 01; 97(5):1147-55. PMID: 12599219.
      Citations: 12     Fields:    Translation:Humans
    68. Harrison RV, Janz NK, Wolfe RA, Tedeschi PJ, Chernew M, Stross JK, Huang X, McMahon LF. Personalized targeted mailing increases mammography among long-term noncompliant medicare beneficiaries: a randomized trial. Med Care. 2003 Mar; 41(3):375-85. PMID: 12618641.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    69. Huang X, Wolfe RA. A frailty model for informative censoring. Biometrics. 2002 Sep; 58(3):510-20. PMID: 12229985.
      Citations: 26     Fields:    Translation:Humans
    70. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Research and Treatment. 154:495-508.
    71. Maximum likelihood estimation of semiparametric mixture component models for competing risks data. Biometrics. 70:588-598.
    72. Efficient semiparametric mixture inferences on cure rate models for competing risks. Canadian Journal of Statistics. 43:420-435.
    73. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Science Translational Medicine. 8.
    74. Mitochondrial profiling of acute myeloid leukemia in the assessment of response to apoptosis modulating drugs. PLoS One. 10.
    75. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia.
    76. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology.
    77. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    78. A semiparametric inverse-Gaussian model and inference for survival data with a cured proportion. Canadian Journal of Statistics. 42:635-649.
    79. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia. The Lancet Haematology.
    80. Adaptive and sequential methods for clinical trials. Journal of Probability and Statistics.
    81. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia.
    82. A Bayesian multivariate joint frailty model for disease recurrences and survival. Statistics in Medicine. 35:4794-4812.
    83. On the dependence structure of bivariate recurrent event processes. Biometrika. 102:345-358.
    84. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Science Signaling. 9.
    85. Joint frailty models for zero-inflated recurrent events in the presence of a terminal event. Biometrics. 72:204-214.
    86. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms. The Lancet Oncology. 18:100-111.
    87. Quantile residual life regression with longitudinal biomarker measurements for dynamic prediction. Journal of the Royal Statistical Society. Series C: Applied Statistics.
    88. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. The Lancet Oncology. 16:1547-1555.
    89. Optimization of multi-stage dynamic treatment regimes utilizing accumulated data. Statistics in Medicine. 34:3424-3443.
    90. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. American Journal of Hematology.
    91. A two-stage approach for dynamic prediction of time-to-event distributions. Statistics in Medicine.
    92. Results of the phase i trial of RG7112, a small-molecule MDM2 antagonist in leukemia. Clinical Cancer Research. 22:868-876.
    93. Comparison of Analytic Methods for Quantitative Real-Time Polymerase Chain Reaction Data. Journal of Computational Biology. 22:988-996.
    94. Decitabine response with chromosome 7 abnormality in MDS, and decitabine optimal schedule [10]. Blood. 110:1083.
    95. Joint analysis of correlated repeated measures and recurrent events processes in the presence of death, with application to a study on acquired immune deficiency syndrome. Journal of the Royal Statistical Society. Series C: Applied Statistics. 58:65-81.
    96. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.
    97. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 30:268-273.
    98. Modified SuperCurve Method for Analysis of Reverse-Phase Protein Array Data. Journal of Computational Biology. 22:765-769.
    HUANG's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (342)
    Explore
    _
    Co-Authors (74)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _